What a pain management practice should ask for before ordering
Pain management and physical medicine groups considering a new biologics line typically request the lot-specific certificate of analysis, donor eligibility summary, and lot release record before committing to a first order.
Donors are screened through a review of medical and social history and serology testing for communicable disease at the time of a scheduled, full-term C-section delivery; donation does not affect a mother's option to also bank cord blood. Practices can request that donor eligibility summary for the specific lot they intend to order.
For exosome products, Precision Biologics also shares the available characterization data (assay results, particle counts, and marker identification reported by the supplier) strictly as analytical findings, not as claims about what the product does once administered.
New York
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
866- Pain Medicine
- 354
- Physical Medicine & Rehabilitation
- 512
NPI-verified ordering
Every account is opened for a licensed professional and checked against an NPI number before the first shipment goes out; Precision Biologics does not sell to patients or unverified buyers.
Multi-site pain and rehab groups can register more than one location under one account, provided each ordering physician is separately verified against the NPPES registry.
Logistics for interventional and rehab settings
Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and require storage at -80 degrees Celsius on arrival, which suits practices with a dedicated procedure suite and freezer capacity.
Lyophilized exosome and Wharton's jelly formats are shelf-stable and skip that cold chain, an option some multi-location pain groups prefer for satellite offices without ultra-low freezers. Both formats are tracked by lot number at the patient-record level once received.
Checking your regulatory posture
Precision Biologics does not advise on dosing, injection technique, or which pain indications a product might be used for; those are clinical and regulatory decisions that belong to the treating physician and the practice's compliance staff.
We recommend confirming any New York-specific licensing or scope-of-practice questions with the New York State medical board and your own counsel before adding a new product line.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management group with multiple New York locations use one Precision Biologics account?+
Yes, provided each location's ordering physician completes separate NPI verification.
Does Precision Biologics provide dosing or injection protocols for pain practices?+
No. Precision Biologics distributes product and supporting documentation only; clinical use decisions remain with the practice and its own medical and legal counsel.
What's the difference between the cryopreserved and lyophilized options for a rehab practice?+
Cryopreserved Wharton's jelly products require -80 degree Celsius storage and overnight dry-ice shipping, while lyophilized formats are shelf-stable; which format fits a given location is a practice decision based on storage capacity.